Meet the team behind the hereditary cancer testing service
The BRCATESTUK hereditary cancer testing service was launched in the UK in December 2016.
It is a comprehensive service developed by Everything Genetic Ltd with the clinical support of Innermost Healthcare and the Color panel test.
We also have an unpaid Medical Advisory team – not contracted to BRCATESTUK – which includes one of Britain's top breast surgeons in Professor Kefah Mokbel, one of the UK’s most respected ovarian cancer experts in Dr Adam Rosenthal, and Innermost Healthcare's Consultant in Fetal Medicine, Bryan Beattie.
We also have a post-test support team of Clinical Genetics experts, including Dr Alexandra Murray (Cardiff), genetic counsellor Lucy Burgess and Dr Gabriella Pichert, who are ready to receive patients for positive results. The support team members are not contracted to BRCATESTUK and solely support the post test referral pathway.
All our doctors can also be independent sources to discuss any other result found on the report at the cost of the patient themselves.
Clinical and commercial leads
Dr Bryan Beattie
Dr Bryan Beattie MD FRCOG is BRCATESTUK's Clinical Lead.
He is also Innermost Healthcare's Medical Director and an accredited subspecialist Consultant in Fetal Medicine based at the University Hospital of Wales in Cardiff.
Dr Beattie was responsible for setting up the Early Pregnancy Assessment Unit at the University Hospital of Wales, and holds the Royal College of Obstetricians and Gynaecologists / Royal College of Radiologists Joint Diploma in Advanced Obstetric Ultrasound and is accredited by the RCOG as being Subspecialty Trained in Fetal Medicine.
He has been performing obstetric ultrasound scans for over 18 years and is a Director of the BUMPS, now MUMS, UK Network.
Research: Doppler ultrasound in normal and high risk pregnancy. Stem Cell Research.
James Price is BRCATESTUK's Commercial and reimbursement lead.
James is also the owner and CEO of Everything Genetic Ltd, one of the organisations behind BRCATESTUK. A commercial leader with a strong commercial skillset and a track record of working in the molecular diagnostics and genetic testing space, James has found great success in the women’s health sector and other markets within molecular testing.
He built the UK and Ireland genetic testing business Myriad Genetics Ltd, launching the BRACanalysis and Endopredict tests in to the market.
From KOL engagement, strategic planning through to product launch, he also built the commercial structure of the national business from scratch, following other successful sales roles for companies such as Qiagen, Hamilton, Gen-Probe, Hologic and Abcodia.
Claire Donovan, BSc.Econ, MSc.Econn
Claire is BRCATESTUK's Corporate Governance and Policy Consultant. She is an experienced health service management professional, having served 17 years in the NHS in the United Kingdom.
Her public sector tenure included roles in public health, health care commissioning and most recently as a Business Director & Board Member of a local health board and as a Senior Associate writing national policy documentation for the NHS in Wales.
Her career is now in the private sector, founding and leading her own retail company and acting as a corporate governance and policy consultant to private healthcare firms.
She is a former Police Lay Visitor and is now a Trustee of the Innermost Learning Charity.
Medical advisory team
Professor Kefah Mokbel MB,BS MS FRCS
Professor Kefah Mokbel FRCS is lead breast surgeon at the London Breast Institute of the Princess Grace Hospital, Professor (Honorary) of Breast Cancer Surgery at The Brunel Institute of Cancer Genetics and Pharmacogenomics (London, UK), the founder and current president of Breast Cancer Hope, and the founder of the website Breast Specialist.
UK charity Breast Cancer Hope aims to improve the quantity and quality of life in women diagnosed with breast cancer, while Breast Specialist (www.breastspecialist.co.uk) aims to present women with the latest medical information regarding breast cancer and common breast conditions in a reader-friendly format.
The information provided on his website enables women with breast symptoms to understand their conditions more fully, helping to alleviate any anxieties, and allowing them to actively participate in their treatment.
Professor Mokbel was named as one of Britain’s Top Doctors by The Times newspaper in 2010 and named by Tatler as one of Britain’s best breast surgeons in 2006, 2007 and 2013.
Professor Andrew Baildam MD FRCS
Professor Andrew Baildam trained in Surgical Oncology and then additionally breast plastic and reconstructive surgery before being appointed as Consultant Surgeon and Honorary Senior Lecturer in Surgical Oncology at The Christie Hospital in Manchester UK.
Subsequently he was appointed to St Bartholomew's Hospital in London as the Professor of Breast and Oncoplastic Surgery to the Queen Mary University of London. During his training he took two years in London and Manchester to research into the molecular biology of breast cancer, leading to a Doctoral Thesis.
With a keen interest in the care of patients with genetic breast cancer and oncoplastic breast surgery, he is hugely experienced in risk-reducing surgery and breast reconstruction. He has more than 180 peer-reviewed publications, abstracts and chapters, and has innovated a number of approaches to breast cancer surgery.
He has also held several positions including being the past President of BASO – The Association of Cancer Surgery and the Chair of Royal College of Surgeons of England Cancer Surgery Committee. He is a member of BAPRAS, the association of plastic and reconstructive surgeons.
Of note, he set up the cross specialty breast surgery oncoplastic fellowships in the UK, leading to a better-structured oncoplastic programme for surgical trainees. He is enthusiastic and passionate both for the highest quality care for patients, and for inspiration of trainees, and has a high tertiary referral surgical practice in Manchester at the Alexandra Hospital and London at King Edward VII Hospital.
He can be reached via his office at email@example.com, or by phone at 0161 4912 153. He teaches and lectures widely and spends off-work time climbing mountains and enjoying music and art.
Dr Adam Rosenthal
Dr Adam Rosenthal PhD FRCOG is one of the UK’s most respected ovarian cancer experts, with over 20 years of specialisation in the field of inherited gynaecological cancer and ovarian cancer screening.
He is a practicing gynaecological surgeon and researcher at University College London. He is the clinical lead on the world's largest study of screening for women at high risk of ovarian cancer; the UK Familial Ovarian Cancer Screening Study (UKFOCSS).
He also practises at The Princess Grace, Highgate and Weymouth Street Hospitals as well as leading the private ovarian cancer screening service at The London Ultrasound Centre. Dr Rosenthal is a medical advisor to the Eve Appeal and Ovacome charities. He has sat on the steering committee of the UK Cancer Genetics Group and has given numerous interviews to the UK media, including Channel 4 News and Radio 5 Live.
He is passionate about the importance of establishing a person’s inherited risk of cancer so they can take measures to protect themselves and their blood relatives from developing the disease.
For private consultations please call Patricia Lewis on 020 7387 8297 or email firstname.lastname@example.org
Lucy Burgess RN, DPSN, BSc (Hons), PGDip Advanced Practice, Cert Counselling, PGDip Research, PGDip Genomic Medicine
Lucy Burgess has over 17 years of experience working as a genetic counsellor for the West Midlands Clinical Genetics Service in Birmingham specialising in cancer genetics. Prior to her appointment in 2000 as one of the country’s first Macmillan Cancer Genetic Counsellors she worked widely in the field of cancer care and as an Oncology Clinical Nurse Specialist at the Queen Elizabeth Hospital in Birmingham.
Lucy helped set up the West Midlands Family Cancer Service and is currently involved in the West Midlands Mainstream Genetic Testing Project (GENERATE), particularly concerning the patient experience pathway. She has been involved several research and audit projects and is an author and co-author of a number of publications and cancer genetic book chapters.
She is particularly interested in familial breast, ovarian and bowel cancer and also in inherited paraganglioma and phaeochromocytoma.
Lucy can provide an assessment of cancer risk for families and individuals provide genetic counselling, support and advice. She can also arrange genetic testing, organise management plans and referrals to medical specialists. She can be contacted directly by e-mail on email@example.com or by phone on 07779 017848.
Dr Alexandra J Murray MBBS, MSc, FRCP, Consultant Clinical Geneticist
Dr Murray is the Cancer Genetics Lead Clinician for the All Wales Medical Genetics Service, based at the University Hospital of Wales in Cardiff and Singleton Hospital in Swansea.
She is a member of the Wales Cancer Network and is leading the Welsh cancer genetics mainstreaming programme.
She has a particular interest in familial breast and ovarian cancer and is the local principal investigator for several UK-wide breast cancer research studies including the Breast and Ovarian Cancer Susceptibility Study and the Epidemiological Study of Familial Breast Cancer.
She has been involved in numerous local research and service evaluation projects and has used the outcomes of these to improve the cancer genetics patient experience.
She is a member of the Target Ovarian Cancer Clinical Advisory Panel.
Dr Gabriella Pichert
Dr. Pichert has specialised in medical oncology but since 1999 her focus has been on cancer genetics, where she has acquired broad knowledge in risk assessment, genetic counselling and management of individuals and families with an inherited predisposition to cancer.
With a background in oncology, Dr Pichert worked as a Consultant in Cancer Genetics in the Department of Clinical Genetics at Guy’s and St Thomas NHS Foundation Trust from 2004 to 2010 and was Joint Lead for Cancer Genetic Services from 2008-2010. During that time Dr Pichert developed a multidisciplinary clinic for the management of carriers with mutations in the BRCA1 and BRCA2 genes and established a multidisciplinary clinic for families with an inherited predisposition to skin cancers.
One of the few Cancer Geneticists in private practice in London, Dr Pichert has established a clinic at London Bridge Hospital and can receive referrals from oncologists, GP’s, gastroenterologists, kidney specialists, dermatologists, breast specialists, gynaecologists, urologists and colorectal surgeons.
Dr Pichert provides cancer risk assessment, genetic counselling and advice on the management of individuals and families with an inherited predisposition to cancer, such as women with a personal and/or family history of breast cancer.
Professor Gareth Evans
Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer.
He has published 660 peer reviewed research publications; 247 as first or senior author.
He has published over 100 reviews and chapters and has had a book published by Oxford University Press on familial cancer.
He has an ISI web of knowledge H-index of 90 and google scholar of 123 having only published his first article in 1990.
In the last 7 years he has raised over £45 million in grants for multicentre and local studies – approximately £38 million to Manchester.
He is Chief Investigator on two NIHR program grants (2009-2014-£1.59 million) (2017-2020-£1million) on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011).
He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service.
He is overall cancer lead (3 themes) and Cancer Prevention Early detection theme lead on the successful all Manchester NIHR Biomedical research centre bid (2017-2022-£28.5million).
He is lead clinician on the NICE familial breast cancer guideline group and is a trustee of BCN and the Neuro Foundation.
Want to get involved? Join the team.
We are currently recruiting more clinical geneticists across the country to support our patients. Get in touch if you would like us to refer patients to you in your area and be part of the BRCATESTUK team!
Why have the test?
We test for the mutations in up to 30 genes that significantly increase the risk of common cancers such as breast, bowel, ovarian and prostate cancer.
Why have the test?
With BRCATESTUK's simple blood test or do-it-yourself saliva test, you can now screen for the mutations and start to take action straight away.
Why have the test?
Your results could affect your relatives too – if a man carries a mutation in BRCA1, each of his children has a 50% chance of carrying the same mutation.